M. Kinzig-Schippers

Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin (2007)

Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig-Schippers, M., Bulitta, J. B., Holzgrabe, U., Drusano, G. L., ...

Flucloxacillin is often used for the treatment of serious infections due to sensitive staphylococci. The pharmacokinetic (PK)-pharmacodynamic (PD) breakpoint of flucloxacillin has not been determined...

Continuous vs bolus administration of imipenem in critically ill patients with ICU-acquired pneumonia (2004)

Sakka, S, Glauner, A, Bulitta, J, Kinzig-Schippers, M, Sörgel, F

No abstract available.

Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure (2004)

Jetter, A., Kinzig-Schippers, M., Illauer, M., Hermann, R., Erb, K., Borlak, J., ...

BACKGROUND AND OBJECTIVE: The standard approach for phenotyping of the human arylamine N-acetyltransferase 2 (NAT2) uses urinary caffeine metabolite ratios after a caffeine test dose taken in after...

Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Nau, R, Kinzig-Schippers, M, Sörgel, F, Schinschke, S, Rössing, R, Müller, C, ...

Its broad antibacterial spectrum qualifies the combination of piperacillin and tazobactam for therapy of nosocomial bacterial central nervous system (CNS) infections. Since these infections sometimes...

Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Nau, R, Kinzig-Schippers, M, Sörgel, F, Schinschke, S, Rössing, R, Müller, C, ...

Its broad antibacterial spectrum qualifies the combination of piperacillin and tazobactam for therapy of nosocomial bacterial central nervous system (CNS) infections. Since these infections sometimes...

Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers▿

Bulitta, J. B., Duffull, S. B., Kinzig-Schippers, M., Holzgrabe, U., Stephan, U., Drusano, G. L., ...

Respiratory tract infections cause 90% of premature mortality in patients with cystic fibrosis (CF). Treatment of Pseudomonas aeruginosa infection is often very problematic. Piperacillin-tazobactam...

Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis▿

Louie, A., Heine, H. S., Kim, K., Brown, D. L., VanScoy, B., Liu, W., ...

Simulating the average non-protein-bound (free) human serum drug concentration-time profiles for linezolid in an in vitro pharmacodynamic model, we characterized the pharmacodynamic parameter(s) of...